Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesGoodwill & IntangiblesIntangiblesLiabilities and Shareholders EquityNon-Current AssetsOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Property, Plant & Equipment (Net)Retained EarningsShareholder's EquityShares OutstandingShort-term InvestmentsTotal Current LiabilitiesTotal Liabilities
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Tvardi Therapeutics (TVRD) Preferred Stock Liabilities (2023 - 2025)

Tvardi Therapeutics' Preferred Stock Liabilities history spans 4 years, with the latest figure at $85.5 million for Q1 2025.

  • On a quarterly basis, Preferred Stock Liabilities changed 0.0% to $85.5 million in Q1 2025 year-over-year; TTM through Mar 2025 was $85.5 million, a 0.0% change, with the full-year FY2024 number at $85.5 million, changed 0.0% from a year prior.
  • Preferred Stock Liabilities hit $85.5 million in Q1 2025 for Tvardi Therapeutics, roughly flat from $85.5 million in the prior quarter.
  • Over the last five years, Preferred Stock Liabilities for TVRD hit a ceiling of $85.5 million in Q4 2023 and a floor of $85.5 million in Q4 2023.
  • Historically, Preferred Stock Liabilities has averaged $85.5 million across 3 years, with a median of $85.5 million in 2023.
  • The widest YoY moves for Preferred Stock Liabilities: up 0.0% in 2024, down 0.0% in 2024.
  • Tracing TVRD's Preferred Stock Liabilities over 3 years: stood at $85.5 million in 2023, then changed by 0.0% to $85.5 million in 2024, then changed by 0.0% to $85.5 million in 2025.
  • Business Quant data shows Preferred Stock Liabilities for TVRD at $85.5 million in Q1 2025, $85.5 million in Q4 2024, and $85.5 million in Q3 2024.